Inflammation markers in patients with cardiovascular disease and metabolic syndrome

Journal of Medical Biochemistry

Langlois Michel¹  Blaton Victor¹  Korita Irena²  Bulo Anyla² 

[1] AZ St Jan AV Department of Clinical Chemistry Brugge, and KU-Leuven, Belgium;Laboratory Department, Faculty of Medicine, University Hospital Centre "Mother Teresa", Tirana, Albania;

关键词: metabolic syndrome;    inflammation;    oxidative stress;    stenosis;    hdl lipoproteins;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: The clinical value and the interrelationship of HDL and the metabolic syndrome were studied using plasma levels of TNF-α, IL 6, IL 10, IL 8, IL 1beta, IL 2R in patients with cardiovascular stenosis. Methods: On the basis of exclusion criteria, we recruited 198 male and female patients aged 45 to 75 years with CVD and 43 patients with MS. Patients were subdivided into %stenosis according to the CASS guidelines. Lipids were measured on an Olympus AU640 analyzer. Ox-LDL was measured by the immunosorbent assay and MDA by HPLC. Cytokines were analysed with DPC Immulite 1000. Statistical tests were performed using SPSS for Windows, 14.0 & Medcalc. Results: Ox-LDL and apoB were significantly higher in the MS(+) patient group (88.7 U/L) compared to the MS(-) group (77.5 U/L). Ox-LDL showed a positive correlation (P=0.001) with LDL-C, apoB and MDA. There was a higher concentration of HDL in the patient group MS(-), which was confirmed by a non-significant (P=0.849) change of apoA(I) from 1.267 g/L in the MS(+) to 1.275 g/L in the MS(-) group. A light significant increase of IL 10 (P=0.05) in MS(+) patients was observed, and the other analysed inflammation markers were mostly unchanged. MS has no direct association with the cytokine production. Conclusions: Ox-LDL and apoB were significantly higher in the MS(+) patient group. In a multiple regression analysis for ox-LDL, apoB (P=0.003) emerged as a strong predictor of the ox-LDL concentration, independent of age, gender, BMI and smoking.

【 授权许可】

Unknown